Regarding Cleveland BioLabs's radiation protection platform, the analyst observed that the Company’s commercial opportunities fall into two primary categories.
The first is the HHS (Department of Health and Human Services) and BARDA (Biomedical Advanced Research and Development Authority) category, which deals with unintended radiation exposure. He stated that the Company has a unique opportunity to address radiation exposure, since there are not currently any existing products available that offer meaningful solutions.
In addition, the analyst noted the Company's potential for traditional medical indications for the same technology.
Posted by DallasInvestor on :
Latest CBLI Video Podcast Now Showing on Firestocks.com
In addition to highlighting recent developments at the Company, the interview featured commentary from Stephen Brozak of WBB Securities, LLC that recently initiated coverage of Cleveland BioLabs with a Buy rating.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses.
The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.
Posted by DallasInvestor on :
Several New Developments Send Strong Signal
Four Company Developments Have Strong Potential A successful response to the DOD's RFP and further development of Protectan CBLB502, which the Company forecasts to generate revenues in 2008
The launch of additional Phase II clinical trials for Curaxin CBLC102
The progress of their potential stem cell applications from research, to clinical development
The movement of their radiation protection compounds into human studies, in new therapeutic areas, such as supportive care for cancer and acute organ failure.